Amedisys Shows Rising Relative Price Performance; Still Shy Of Key Threshold

The Relative Strength (RS) Rating for Amedisys (AMED) headed into a new percentile Tuesday, as it got a lift from 66 to 72.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the last 52 weeks compares to all the other stocks in our database.

History shows that the stocks that go on to make the biggest gains often have an RS Rating of above 80 in the early stages of their moves. See if Amedisys can continue to rebound and hit that benchmark.

See How IBD Helps You Make More Money In Stocks

Amedisys has climbed more than 5% past a 249.06 entry in a fourth-stage flat base, meaning it’s now out of a proper buy zone. Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.

The company saw both earnings and sales growth rise last quarter. Earnings-per-share increased from 11% to 95%. Revenue rose from -2% to 10%. Look for the next report on or around Feb. 18.

The company holds the No. 1 rank among its peers in the Medical-Outpatient/Home Care industry group.


Which Stocks Are Showing Improved Price Performance?

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

Identify Bases And Buy Points With Pattern Recognition From MarketSmith

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button